Immunotherapy plus chemo and radiation for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 75 years old.
- You have been diagnosed with a type of esophageal cancer called 'squamous cell carcinoma' that cannot be removed with surgery because it has grown into nearby tissues or lymph nodes in the chest, but has not spread to distant organs.
- You have not had any previous treatment (chemotherapy, radiation, targeted therapy, or immunotherapy) for this esophageal cancer.
- You are in generally good health (able to do most daily activities without help).
- You do not have any other active cancer, serious heart or lung disease, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial tests if adding radiation before and after standard chemotherapy can help people whose esophageal cancer has come back after initial treatment. It aims to improve control of the cancer while keeping side effects manageable.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.